(Reuters) -The U.S. Food and Drug Administration has accepted Novo Nordisk’s marketing application for an oral version of its weight-loss drug Wegovy and will take a decision by the fourth quarter, the Danish drugmaker said on Friday.
The company’s experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.
Novo Nordisk’s oral GLP-1 drug Rybelsus, which also has the same active ingredient semaglutide, is already approved for blood sugar control in adults with diabetes.
(Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)
Brought to you by www.srnnews.com
